Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

September 22, 2017: By Jon Swedien

GraybugGraybug Vision has begun dosing patients in a Phase I/II clinical trial for GB-102, its lead product candidate for wet age-related macular degeneration (AMD), the Redwood City, California, company announced Sept. 19.

GB-102 is a novel intravitreal (IVT) injectable depot formulation of sunitinib malate, a tyrosine kinase inhibitor that blocks multiple angiogenesis pathways. GB-102 has the potential to be a twice annual treatment for wet AMD, Graybug said.

The two-part study—ADAGIO—will evaluate wet AMD patients currently being treated with available IVT anti-VEGF agents who are then switched over to treatment with GB-102 alone, Graybug said.

Part one is a multicenter, open-label, single IVT injection study of up to four dose levels of GB-102 administered in ascending dosing cohorts, Graybug said. Following the single IVT injection of GB-102, patients will undergo monthly evaluation for eight months to assess safety, tolerability, and functional/pharmacodynamic parameters, including visual acuity and optical coherence tomography (OCT) measures of the retina, Graybug said.

Part two is a multicenter, double-masked, randomized, parallel-group, safety, and efficacy evaluation of repeated IVT injections of two dose levels of GB-102 compared with a standard IVT regimen of aflibercept, Graybug said.

Graybug said it also has a second-generation product under development, GB-103, that has potential to be a once-per-year IVT treatment for wet AMD.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023